Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Cerebrolysin
Also known as: FPF-1070
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from enzymatic breakdown of purified porcine brain proteins. It is an approved drug in many countries (not the US or UK) for stroke, traumatic brain injury, and dementia. It has one of the larger evidence bases in this category, with multiple randomized controlled trials, though results have been mixed and some trials criticized for methodological issues.
Risk Level
Medium RiskDifficulty
Advanced| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
The peptide mixture mimics endogenous neurotrophic factors, activating signaling pathways similar to BDNF, GDNF, NGF, and CNTF. Promotes neuronal survival, neurite outgrowth, synaptic plasticity, and neurogenesis. Also shows anti-apoptotic and antioxidant properties in neural tissue.
Dosing Research
Clinical doses: 10-30 mL IV infusion daily for 10-20 days. Some protocols use 5 mL IM for mild cognitive impairment. Underground use follows clinical protocols. Must be administered parenterally as the peptides are not orally bioavailable. Repeated courses may be given with 2-3 month intervals.
Side Effects & Risks
Generally well-tolerated in clinical trials. Common side effects include dizziness, headache, insomnia, and injection site reactions. Rare reports of agitation, confusion, and allergic reactions. Being a porcine-derived product, there is a theoretical prion/contamination risk.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.